Where is Innoviva (INVA) Headed According to Analysts?

Innoviva, Inc. (NASDAQ:INVA) is one of the best affordable biotech stocks to invest in now. On August 11, H.C. Wainwright analyst Raghuram Selvaraju raised the firm’s price target on Innoviva, Inc. (NASDAQ:INVA) to $45 from $40 while keeping a Buy rating on the shares.

Innoviva, Inc. (INVA): Among Stocks with Insanely High PE Ratios Insiders Are Selling

The same day, Oppenheimer initiated coverage of Innoviva, Inc. (NASDAQ:INVA) with an Outperform rating and $35 price target.

The firm told investors that it considers Innoviva, Inc.’s (NASDAQ:INVA) specialty therapeutics and royalty commercial results to be significant factors that can drive share outperformance.

Innoviva, Inc. (NASDAQ:INVA) is involved in the development, commercialization, and financial management of biopharmaceuticals.

While we acknowledge the potential of INVA to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than INVA and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.